Hospital
Memorial Hospital
Memorial Hospital was paid $15.39M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL
LOGANSPORT, IN 46947
LOGANSPORT, IN 46947
33aNPI1356320469assigned 01/17/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$15.39M
24GClaims386,737
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,994 | $561K | |
| 2019 | 37,728 | $1.20M | |
| 2020 | 34,037 | $1.12M | |
| 2021 | 53,426 | $1.88M | |
| 2022 | 81,445 | $3.54M | |
| 2023 | 83,955 | $3.64M | |
| 2024incomplete | 59,152 | $3.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 23,301 | 19,507 | $3.52M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 27,394 | 22,408 | $3.41M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.1% | 14,396 | 10,915 | $782K |
| 71045 | Radiologic examination, chest; single view | 4.9% | 6,844 | 5,435 | $757K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 5,276 | 4,180 | $599K |
| 87631 | 3.4% | 6,244 | 5,308 | $530K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 2,816 | 2,357 | $425K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 6,929 | 5,320 | $407K |
| 59425 | 2.6% | 1,752 | 1,423 | $396K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 3,814 | 964 | $329K |
| 59426 | 2.1% | 1,396 | 750 | $318K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 8,292 | 7,036 | $245K |
177 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 2,423 | $213K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 5,265 | $193K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,622 | $154K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,205 | $153K |
| 59025 | Fetal non-stress test | <1% | 435 | $148K |
| 80053 | Comprehensive metabolic panel | <1% | 28,955 | $147K |
| 80050 | General health panel | <1% | 800 | $147K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,804 | $135K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,476 | $135K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,438 | $134K |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,836 | $133K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 250 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,450 | $124K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,224 | $110K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 367 | $105K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,490 | $105K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 965 | $100K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,535 | $99K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 602 | $75K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 263 | $64K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 549 | $49K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,332 | $48K |
| 80061 | Lipid panel | <1% | 6,104 | $45K |
| 11721 | <1% | 1,052 | $40K | |
| 73630 | <1% | 1,285 | $38K | |
| 84484 | <1% | 5,923 | $38K | |
| 96127 | <1% | 273 | $29K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,500 | $27K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,862 | $27K |
| 83880 | <1% | 1,343 | $26K | |
| 95812 | <1% | 84 | $24K | |
| 87081 | <1% | 4,653 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,681 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,685 | $23K |
| 84145 | <1% | 1,398 | $22K | |
| 83735 | <1% | 6,017 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,402 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 190 | $21K |
| 92567 | <1% | 211 | $20K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 488 | $20K |
| 83690 | <1% | 5,729 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,295 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 192 | $18K |
| 11102 | <1% | 12 | $17K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 608 | $17K |
| 73130 | <1% | 400 | $17K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 751 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 85 | $15K |
| 95886 | <1% | 158 | $15K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 147 | $14K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 95 | $14K |
| 87660 | <1% | 866 | $12K | |
| 87480 | <1% | 852 | $12K | |
| 87510 | <1% | 851 | $12K | |
| 84703 | <1% | 2,339 | $11K | |
| 86141 | <1% | 1,372 | $10K | |
| 17110 | <1% | 54 | $10K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 644 | $10K |
| 81001 | <1% | 5,550 | $10K | |
| 81003 | <1% | 7,326 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 22 | $9K |
| 95819 | <1% | 18 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 281 | $9K |
| 20610 | <1% | 33 | $8K | |
| 85027 | <1% | 1,475 | $6K | |
| 82150 | <1% | 1,645 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 427 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 97 | $6K |
| 97602 | <1% | 49 | $6K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 40 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 894 | $6K |
| 83655 | <1% | 440 | $5K | |
| 85379 | <1% | 794 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 32 | $5K |
| 86803 | <1% | 466 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 358 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 49 | $4K |
| 83605 | <1% | 572 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 149 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 64 | $4K |
| 87205 | <1% | 1,269 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 737 | $3K |
| 97597 | <1% | 18 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $3K |
| 82607 | <1% | 368 | $3K | |
| 86592 | <1% | 1,138 | $3K | |
| 95937 | <1% | 95 | $3K | |
| 59430 | <1% | 12 | $3K | |
| 90837 | Psychotherapy session, about an hour | <1% | 18 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 218 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $2K |
| 73562 | <1% | 68 | $2K | |
| 71250 | <1% | 16 | $2K | |
| 82553 | <1% | 377 | $2K | |
| 86762 | <1% | 218 | $2K | |
| 97161 | <1% | 14 | $2K | |
| 87807 | <1% | 201 | $2K | |
| 86885 | <1% | 505 | $2K | |
| 95913 | <1% | 19 | $2K | |
| 76770 | <1% | 19 | $2K | |
| 82950 | <1% | 650 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 16 | $2K |
| 82043 | <1% | 423 | $2K | |
| 87340 | <1% | 251 | $1K | |
| 86140 | <1% | 389 | $1K | |
| 82570 | <1% | 403 | $1K | |
| 85610 | <1% | 582 | $1K | |
| 81025 | <1% | 282 | $1K | |
| 84702 | <1% | 169 | $1K | |
| 82565 | <1% | 348 | $1K | |
| 85730 | <1% | 387 | $1K | |
| 87150 | <1% | 98 | $1K | |
| 87653 | <1% | 44 | $1K | |
| 85651 | <1% | 394 | $1K | |
| 86901 | <1% | 465 | $910.11 | |
| 86900 | <1% | 465 | $910.03 | |
| 82550 | <1% | 294 | $804.06 | |
| 87040 | <1% | 161 | $764.66 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 29 | $725.29 |
| 85018 | <1% | 501 | $698.38 | |
| 85014 | <1% | 501 | $696.82 | |
| 83970 | <1% | 33 | $526.47 | |
| 80076 | <1% | 96 | $438.71 | |
| 83021 | <1% | 45 | $427.24 | |
| 82652 | <1% | 15 | $423.50 | |
| 84450 | <1% | 119 | $414.10 | |
| 88304 | <1% | 59 | $368.00 | |
| 84156 | <1% | 149 | $330.95 | |
| 82040 | <1% | 98 | $322.29 | |
| 87486 | <1% | 14 | $285.64 | |
| 87581 | <1% | 14 | $256.48 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 14 | $256.48 |
| 94726 | <1% | 17 | $254.60 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 18 | $221.13 |
| 86160 | <1% | 14 | $168.49 | |
| 87503 | <1% | 15 | $164.46 | |
| 86200 | <1% | 13 | $155.10 | |
| 96376 | <1% | 96 | $147.42 | |
| 82465 | <1% | 80 | $129.70 | |
| 83615 | <1% | 33 | $127.92 | |
| 86225 | <1% | 13 | $118.48 | |
| 86038 | <1% | 18 | $117.67 | |
| 81000 | <1% | 64 | $116.42 | |
| 84439 | <1% | 15 | $104.67 | |
| 86787 | <1% | 15 | $97.04 | |
| 84550 | <1% | 33 | $95.72 | |
| 82947 | <1% | 42 | $60.25 | |
| 86593 | <1% | 12 | $45.48 | |
| 87070 | <1% | 26 | $25.08 | |
| 87075 | <1% | 26 | $24.69 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 302 | $10.30 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,384 | $1.89 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 2,117 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,140 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 301 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 85 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 106 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 60 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 368 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 218 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 55 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 83 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 238 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 24 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 56 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 66 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,344 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,722 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 14 | $0.00 |
| 90715 | 0% | 143 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 93 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 190 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 40 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 15 | $0.00 |
| 94729 | 0% | 14 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRISSER, STANTON (ACFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.